نتایج جستجو برای: mtd

تعداد نتایج: 1531  

2011
Beata Holkova E. Brent Perkins Viswanathan Ramakrishnan Mary Beth Tombes Ellen Shrader Neha Talreja Martha D. Wellons Kevin T. Hogan G. David Roodman Domenico Coppola Loveleen Kang Jana Dawson Robert K. Stuart Cody Peer William D. Figg Sarah Kolla John Wright Daniel M. Sullivan John D. Roberts Steven Grant

Purpose: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B-cell malignancies (multiple myeloma, indolent lymphoma, and mantle cell lymphoma). Experimental Design: Patients received bortezomib by intravenous push on days 1, 4, 8, and 11. Patients also received alvocidib...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2014
B Rini B Redman J A Garcia H A Burris S Li A Fandi R Beck U Jungnelius J R Infante

BACKGROUND This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of lenalidomide plus sunitinib in metastatic renal cell carcinoma (RCC) patients. PATIENTS AND METHODS Patients with histologically confirmed, metastatic RCC were treated with 10 mg/day lenalidomide plus 37.5 mg/day sunitinib, orally in 21-day cycles. Doses were escalated to dete...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Sarah Blagden Aurelius Omlin Debra Josephs Chara Stavraka Andrea Zivi David J Pinato Alan Anthoney Shaun Decordova Karen Swales Ruth Riisnaes Lorna Pope Kohei Noguchi Rie Shiokawa Michiyasu Inatani Jenny Prince Keith Jones Chris Twelves James Spicer Udai Banerji

PURPOSE This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of CH5132799. EXPERIMENTAL DESIGN Patients with metastatic solid tumors were eligible for the study. CH5132799 was administered orally once daily or twice daily in 28-day cycles. RESU...

Journal: :The Kurume medical journal 2009
Yutaka Ogata Teruo Sasatomi Yoshito Akagi Nobuya Ishibashi Shinjirou Mori Kazuo Shirouzu

The anti-angiogenic efficacy of chemotherapy would seem to be optimized by administering comparatively lower doses of drugs on a more frequent (daily, several times a week, or weekly) or continuous schedule, with no extended interruptions - sometimes referred to as 'metronomic' chemotherapy. This phase I study was performed to determine the recommended dosage (RD) of metronomic chemotherapy usi...

Journal: :International journal of radiation oncology, biology, physics 2011
Phioanh Leia Nghiemphu Patrick Y Wen Kathleen R Lamborn Jan Drappatz H Ian Robins Karen Fink Mark G Malkin Frank S Lieberman Lisa M DeAngelis Alejandro Torres-Trejo Susan M Chang Lauren Abrey Howard A Fine Alexis Demopoulos Andrew B Lassman Santosh Kesari Minesh P Mehta Michael D Prados Timothy F Cloughesy

PURPOSE To determine the maximum tolerated dose (MTD) of tipifarnib in combination with conventional radiotherapy for patients with newly diagnosed glioblastoma. The MTD was evaluated in three patient cohorts, stratified based on concurrent use of enzyme-inducing antiepileptic drugs (EIAED) or concurrent treatment with temozolomide (TMZ): Group A: patients not receiving EIAED and not receiving ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Beata Holkova E Brent Perkins Viswanathan Ramakrishnan Mary Beth Tombes Ellen Shrader Neha Talreja Martha D Wellons Kevin T Hogan G David Roodman Domenico Coppola Loveleen Kang Jana Dawson Robert K Stuart Cody Peer William D Figg Sarah Kolla Austin Doyle John Wright Daniel M Sullivan John D Roberts Steven Grant

PURPOSE A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B-cell malignancies (multiple myeloma, indolent lymphoma, and mantle cell lymphoma). EXPERIMENTAL DESIGN Patients received bortezomib by intravenous push on days 1, 4, 8, and 11. Patients also received alvocidib...

2013
Nilesh A. Patankar Julia Pritchard Mariska van Grinsven Maryam Osooly Marcel B. Bally

Purpose: To provide proof-of-concept data to support use ofDoxil–liposomal topotecan (Topophore C) combinations to treat ovarian cancer. Experimental Design: ES-2, OVCAR-3, and SKOV-3 ovarian cancer cell lines were treated with doxorubicin–topotecan combinations by exposing the cells to drugs from 1 to 72 hours. Pharmacokinetic analysis was conducted following administration of liposomal formul...

Journal: :Journal of speech, language, and hearing research : JSLHR 2008
Christopher Dromey Shawn L Nissen Nelson Roy Ray M Merrill

PURPOSE Primary muscle tension dysphonia (MTD), a voice disturbance that occurs in the absence of structural or neurological pathology, may respond to manual circumlaryngeal techniques, which ostensibly alter the posture of the larynx and/or the configuration of the vocal folds without directly targeting supralaryngeal articulatory structures. Although the phonatory benefits of these techniques...

Journal: :The Journal of biological chemistry 2004
James S Friedman Hemant Khanna Prabodh K Swain Raphael Denicola Hong Cheng Kenneth P Mitton Christian H Weber David Hicks Anand Swaroop

The basic motif-leucine zipper (bZIP) transcription factor NRL controls the expression of rhodopsin and other phototransduction genes and is a key mediator of photoreceptor differentiation. To delineate the molecular mechanisms underlying transcriptional initiation of rod-specific genes, we characterized different regions of the NRL protein using yeast-based autoactivation assays. We identified...

Journal: :Investigative ophthalmology & visual science 2018
Mieko Yanagisawa Takehiro Yamashita Masato Matsuura Yuri Fujino Hiroshi Murata Ryo Asaoka

Purpose To investigate the relationship between axial length (AL) elongation and progression of primary open-angle glaucoma (POAG). Methods AL was measured twice over a 5.1 ± 0.76 (mean ± standard deviation: SD) year period in 125 eyes of 72 patients with POAG. The eyes were divided into not long (AL < 26 mm, 80 eyes) and long (>26 mm, 45 eyes) groups. During this period, patients' visual fie...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید